|Roche Initiates Early Stage Trial In Down Syndrome. Valeant Announces Mailing Of Offer And Take-Over Bid Circular To Shareholders Of Afexa.|
|By Staff and Wire Reports|
|Friday, 09 September 2011 20:13|
Roche Holding AG (OTC:RHHBY) announced the initiation of its first Phase 1 clinical trial to investigate the safety and tolerability of a molecule designed to address the cognitive and behavioral deficits associated with Down syndrome.
"This study will target only adults between 18 and 30 years old, but we believe that an earlier intervention in Down syndrome has the potential for a greater medical impact," says Paulo Fontoura, Head of Translational Medicine in the Roche Neurosciences Disease Translational Area.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) announced that Valeant mailed to the shareholders of Afexa Life Sciences Inc. (OTC:AFXSF) its offer and take-over bid circular in connection with the previously announced friendly offer (Offer) for all of the outstanding common shares of Afexa (Common Shares) at a price of CDN$0.71 in cash per Common Share. The Offer expires at 5:00p.m. (Edmonton Time) on October 17, 2011, unless otherwise extended or withdrawn.
The Offer represents a premium of approximately 30% to Afexa's 30-trading day volume weighted average closing price on the Toronto Stock Exchange (TSX) as of August 29, 2011 (the day before the announcement of the Offer),
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at the Rodman & Renshaw Global Investment Conference in New York, NY at The Waldorf Astoria.
China Botanic Pharmaceutical Inc. (AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that it will host a conference call at 9:00 a.m. Eastern Time on Thursday, September 15, 2011, to discuss financial results for the third quarter of fiscal year 2011 ended July 31, 2011.
Cortex Pharmaceuticals, Inc. (OTCBB: CORX) President and CEO, Mark A. Varney, Ph.D., will present at Rodman & Renshaw’s 13th Annual Healthcare Conferenceat 4:55 PM (EST) on Monday, September 12, 2011 in the Starlight North Salon at the Waldorf=Astoria Hotel in New York City.
Emergent BioSolutions Inc. (NYSE:EBS) is co-hosting “Anthrax: Threat and Response,” a conference organized by the French High Committee for Civil Defense to discuss anthrax preparedness and response.
Exelixis, Inc. (NASDAQ:EXEL) announced today that Michael Morrissey, PhD, the company’s president and chief executive officer, will present at two upcoming investor conferences. Morgan Stanley Global Healthcare Conference: Exelixis’ presentation will take place at 10:20 a.m. EDT on Tuesday, September 13, 2011, in New York.
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that it is scheduled to make an investor presentation at the Rodman & Renshaw Annual Global Investment Conference Tuesday, September 13, 2011, at 10:50 a.m. Eastern Daylight Time.
Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the Morgan Stanley Global Healthcare Conference will be webcast and may be accessed at www.hgsi.com.
ImmunoCellular Therapeutics, Ltd. (OTC.BB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that the company will present at the Rodman & Renshaw 13th Annual Global Investment Conference at the Waldorf Astoria in New York City on September 13th.
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announced today the actions taken at its Annual Meeting of Stockholders held on September 7, 2011 in New York, New York, USA.
Nektar Therapeutics (Nasdaq: NKTR) announced today that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer were presented at the ASCO 2011 Breast Cancer Symposium in San Francisco, California.
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at two healthcare conferences in September.
Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 13, 2011, at 12:05 p.m. Eastern Time.
PharmAthene, Inc. (NYSE Amex: PIP) announced today that it has achieved significant progress in the development of its second generation anthrax vaccine, SparVax™.
pSivida Corp, (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that it will webcast its live presentation at the Rodman & Renshaw Annual Health Care Conference in New York, Tuesday, September 13.
Retractable Technologies, Inc. (NYSE AMEX: RVP) announced today that its Board of Directors has declared dividends to holders of Series I Class B and Series II Class B Convertible Preferred Stock in the amounts of $18,000 and $54,925, respectively.
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of its first Phase 1 clinical trial to investigate the safety and tolerability of a molecule designed to address the cognitive and behavioral deficits associated with Down syndrome.
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, announced today that an overview of the Company’s business strategy will be given at the Rodman & Renshaw Annual Global Investment Conference, being held at the Waldorf-Astoria Hotel in New York City.
Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE/TSX:VRX), announced today that Valeant mailed to the shareholders of Afexa Life Sciences Inc. ("Afexa") its offer and take-over bid circular in connection with the previously announced friendly offer (the "Offer") for all of the outstanding common shares of Afexa (the "Common Shares") at a price of C$0.71 in cash per Common Share.